cyproterone acetate has been researched along with Local Neoplasm Recurrence in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bono, AV; Brausi, M; Calais da Silva, FE; Calais da Silva, FM; Kirkali, Z; Marques Queimadelos, A; Martin, JA; Robertson, C; Whelan, P | 1 |
| Debré, B; Delongchamps, NB; Peyromaure, M; Zerbib, M | 1 |
| Bruchovsky, N; Crook, J; Gleave, ME; Goldenberg, SL; Klotz, L; Ludgate, C; Malone, S; Morris, WJ | 1 |
| Bruchovsky, N; Crook, J; Goldenberg, SL; Klotz, L | 1 |
| Gobet, DA; Hauri, D; Knönagel, H | 1 |
| Di Lauro, L; Lazzaro, B; Lopez, M; Papaldo, P | 1 |
3 trial(s) available for cyproterone acetate and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cyproterone Acetate; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Gonadotropin-Releasing Hormone; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk Assessment; Survival Analysis | 2009 |
Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Topics: Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Canada; Cyproterone Acetate; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2006 |
Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Testosterone | 2007 |
3 other study(ies) available for cyproterone acetate and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience.
Topics: Aged; Androgen Antagonists; Cyproterone Acetate; Follow-Up Studies; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatectomy; Prostatic Neoplasms; Time Factors | 2005 |
Endocrine treatment prior to radical retropubic prostatectomy in patients with T3 prostate cancer: a retrospective study of 22 patients.
Topics: Aged; Biopsy; Carcinoma; Combined Modality Therapy; Cyproterone Acetate; Humans; Male; Neoplasm Recurrence, Local; Prostate; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Time Factors; Triptorelin Pamoate | 1992 |
Hormonal treatment of disseminated male breast cancer.
Topics: Adult; Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Breast Neoplasms; Castration; Cyproterone; Cyproterone Acetate; Estrogens; Hormones; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen; Time Factors | 1985 |